C92.10
Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
Clinical Classification Guidelines
Inclusion Terms
- Chronic myeloid leukemia, BCR/ABL-positive with failed remission
- Chronic myeloid leukemia, BCR/ABL-positive NOS
Medical Intelligence & Overview
Chronic myeloid leukemia (CML) is a type of blood cancer that originates in the bone marrow, where blood cells are produced. This condition is characterized by the uncontrolled growth of an abnormal type of white blood cell known as the myeloid cell. The specific form described by ICD-10 code C92.10 is BCR/ABL-positive CML that has not responded to treatment and has not achieved remission. This means that the disease persists despite therapy, requiring ongoing management and close medical monitoring.
Causes & Symptoms
Clinical Causes: Genetic mutation involving the Philadelphia chromosome, resulting in the BCR-ABL gene fusion. Inheritance is rare; most cases develop spontaneously. Environmental factors such as exposure to radiation or certain chemicals have been studied but are not definitively linked. Age-related risk factors, with higher incidence in adults, especially those aged 40 to 60.
Key Symptoms: Persistent fatigue and weakness Unintentional weight loss Night sweats and fever Fullness or pain below the ribs on the left side, due to an enlarged spleen Easy bruising or bleeding tendencies Frequent infections Bone pain or tenderness Night sweats or symptoms that do not improve with time
Diagnostic & Treatment
Diagnosis Path: Complete blood count (CBC) showing elevated white blood cell counts Bone marrow biopsy revealing increased myeloid cells Cytogenetic analysis to detect the Philadelphia chromosome Molecular testing for BCR-ABL gene fusion using PCR techniques Additional tests to monitor disease progression and response to treatment
Treatment Protocols: Tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, or nilotinib, which specifically target the BCR-ABL protein Interferon-alpha therapy, though less commonly used today Chemotherapy in certain refractory or advanced cases Stem cell or bone marrow transplantation may be considered for eligible patients Regular monitoring of blood counts and molecular markers to assess treatment response Management of side effects associated with therapies
Clinical Advice & FAQs
Billing Guidance
Is C92.10 a billable ICD-10 code?
Yes, C92.10 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.10?
Clinical documentation must specify the nature of Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference